Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
mg decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 mg » 10 mm (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
mg decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 mg » 10 mm (Expand Search)
-
81
-
82
-
83
-
84
-
85
Weighted odds ratios reflecting the impact of a genetically determined 10 mg/dL decrease in LDL-C on safety and efficacy endpoints.
Published 2020“…<p>Odds ratio and 95% confidence interval is displayed for the effect of a genetically determined 10 mg/dL decrease in LDL-C on safety and efficacy endpoints for White individuals, Black individuals, Hispanic individuals, and inverse variance weighted meta-analysis of White, Black, and Hispanic populations (IVWMA). …”
-
86
Galiellalactone decreases the proportion of ALDH+ prostate cancer cells in vitro and the ALDH1A1 expression in vivo.
Published 2013“…The proportion of ALDH+ cells is expressed as mean ± SEM (n = 2–4). The proportion of ALDH+ DU145 cells were significantly decreased by galiellalactone at the concentrations 10 µM (p = 0.0060), 25 µM (p = 0,0013) and 50 µM galiellalactone (p<0,0001). …”
-
87
-
88
-
89
-
90
-
91
The novel <i>carboxylesterase 1</i> variant c.662A>G may decrease the bioactivation of oseltamivir in humans
Published 2017“…A novel <i>CES1</i> c.662A>G single nucleotide polymorphism (SNP) was predicted to decrease CES1 enzymatic activity in an <i>in silico</i> analysis. …”
-
92
-
93
-
94
Decrease in extracellular Zn<sup>2+</sup> in the hippocampus by zinc chelators.
Published 2013“…<p>Hippocampal slices were prepared 2 h after i.p. injection of vehicle (A, n = 7) or CQ (30 mg/kg, B, n = 5) into NER, and 3 h after i.p. injection of vehicle (C, n = 7) or TPEN (1 mg/kg, D, n = 8) into NER. …”
-
95
PowerPoint Slides for: Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis
Published 2016“…<p><b><i>Background:</i></b> Persistent hyperkalemia (serum potassium (K) ≥5.5 mEq/l) is a common condition in hemodialysis (HD) patients, is associated with increased mortality, and treatment options are limited. …”
-
96
-
97
-
98
-
99
-
100